Stage4Hope

Stage4Hope is a clinical-stage biotechnology company dedicated to the development of innovative therapies for patients with advanced, stage 4 cancers. The company focuses on identifying and targeting specific metabolic and molecular pathways that drive tumor progression and resistance in late-stage disease, particularly in neuro-oncology. Their lead program, S4H-101, is a small molecule metabolic modulator currently being evaluated in Phase 2 clinical trials for the treatment of glioblastoma. Stage4Hope employs a patient-centric approach, aiming to bridge the gap between standard-of-care failures and experimental therapies through targeted clinical development. The company's research is heavily integrated with leading clinical institutions to accelerate the delivery of precision medicines to those with the highest unmet need.